Mesoblast files 6-K on director interest notice

Q: What does Mesoblast Limited (MEOBF) disclose in this Form 6-K?

The Form 6-K states that on January 12, 2026, Mesoblast Limited filed a new issue announcement and a change of director’s interest notice (Appendix 3Y) with the Australian Securities Exchange, and that Appendix 3Y is attached as Exhibit 99.1.

Q: What is Exhibit 99.1 in Mesoblast Limited’s (MEOBF) January 2026 Form 6-K?

Exhibit 99.1 is identified as the Appendix 3Y of Mesoblast Ltd, described as a change of director’s interest notice dated January 12, 2026, which was filed with the Australian Securities Exchange.

Q: Who signed Mesoblast Limited’s (MEOBF) January 2026 Form 6-K?

The Form 6-K is signed on behalf of Mesoblast Limited by Niva Sivakumar, who is identified as the Company Secretary, dated January 12, 2026.

Q: Where is Mesoblast Limited (MEOBF) incorporated and located according to this filing?

Mesoblast Limited is incorporated in Australia, with its principal executive offices at Level 38, 55 Collins Street, Melbourne 3000, Australia, as stated in the Form 6-K.

Mesoblast Limited, an Australia-incorporated company, submitted a Form 6-K as a foreign private issuer for January 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Mesoblast Limited, an Australia-incorporated company, submitted a Form 6-K as a foreign private issuer for January 2026. On January 12, 2026, the company filed a new issue announcement and a change of director’s interest notice (Appendix 3Y) with the Australian Securities Exchange, and attached this Appendix 3Y as Exhibit 99.1 to the Form 6-K. The filing indicates Mesoblast reports under Form 20-F and is signed on behalf of the company by its Company Secretary, Niva Sivakumar.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Mesoblast Limited (MEOBF) disclose in this Form 6-K?

The Form 6-K states that on January 12, 2026, Mesoblast Limited filed a new issue announcement and a change of director’s interest notice (Appendix 3Y) with the Australian Securities Exchange, and that Appendix 3Y is attached as Exhibit 99.1.

What is Exhibit 99.1 in Mesoblast Limited’s (MEOBF) January 2026 Form 6-K?

Exhibit 99.1 is identified as the Appendix 3Y of Mesoblast Ltd, described as a change of director’s interest notice dated January 12, 2026, which was filed with the Australian Securities Exchange.

Which reporting form does Mesoblast Limited (MEOBF) use for its annual reports?

The Form 6-K indicates that Mesoblast Limited files its annual reports under cover Form 20-F rather than Form 40-F.

Who signed Mesoblast Limited’s (MEOBF) January 2026 Form 6-K?

The Form 6-K is signed on behalf of Mesoblast Limited by Niva Sivakumar, who is identified as the Company Secretary, dated January 12, 2026.

Where is Mesoblast Limited (MEOBF) incorporated and located according to this filing?

Mesoblast Limited is incorporated in Australia, with its principal executive offices at Level 38, 55 Collins Street, Melbourne 3000, Australia, as stated in the Form 6-K.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 01/12/2026 - 07:03 PM EST

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of January 2026

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(Jurisdiction of incorporation or organization)

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On January 12, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, change of director’s interest notice (Appendix 3Y) which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited

/s/ Niva Sivakumar

Niva Sivakumar

Company Secretary

Dated: January 12, 2026

INDEX TO EXHIBITS



Item

99.1						Appendix 3Y of Mesoblast Ltd, dated January 12, 2026.

Source: View Original Filing on SEC EDGAR